Therapeutic Solutions International, Inc. (TSOI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.16 Million USD | 41.0% |
| 2022 | -3.67 Million USD | -24.19% |
| 2021 | -2.96 Million USD | -18.66% |
| 2020 | -2.49 Million USD | -21.85% |
| 2019 | -2.04 Million USD | -9.7% |
| 2018 | -1.86 Million USD | -87.54% |
| 2017 | -995.47 Thousand USD | 6.3% |
| 2016 | -1.06 Million USD | -81.17% |
| 2015 | -586.44 Thousand USD | -103.1% |
| 2014 | -288.75 Thousand USD | 47.66% |
| 2013 | -551.65 Thousand USD | 31.52% |
| 2012 | -805.53 Thousand USD | 17.02% |
| 2011 | -970.69 Thousand USD | -111.84% |
| 2010 | -458.22 Thousand USD | 70.2% |
| 2009 | -1.53 Million USD | -1579.66% |
| 2008 | -91.54 Thousand USD | -430.37% |
| 2007 | -17.26 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -585.14 Million USD | -136777.65% |
| 2024 Q2 | -390.04 Thousand USD | 99.93% |
| 2023 Q1 | -270.4 Million USD | -20536.63% |
| 2023 FY | -2.16 Million USD | 41.0% |
| 2023 Q4 | -427.49 Thousand USD | 99.93% |
| 2023 Q3 | -602.04 Million USD | -106948.54% |
| 2023 Q2 | -562.4 Thousand USD | 99.79% |
| 2022 Q1 | -675.14 Thousand USD | 48.95% |
| 2022 Q4 | -1.31 Million USD | -38.44% |
| 2022 Q2 | -1.3 Million USD | -93.46% |
| 2022 Q3 | -946.46 Thousand USD | 27.54% |
| 2022 FY | -3.67 Million USD | -24.19% |
| 2021 Q4 | -1.32 Million USD | -62.31% |
| 2021 Q1 | -186.92 Thousand USD | 77.83% |
| 2021 Q2 | -637.24 Thousand USD | -240.91% |
| 2021 Q3 | -814.79 Thousand USD | -27.86% |
| 2021 FY | -2.96 Million USD | -18.66% |
| 2020 FY | -2.49 Million USD | -21.85% |
| 2020 Q1 | 32.13 Thousand USD | 104.96% |
| 2020 Q2 | -889 Thousand USD | -2866.38% |
| 2020 Q3 | -499.99 Thousand USD | 43.76% |
| 2020 Q4 | -843.03 Thousand USD | -68.61% |
| 2019 Q3 | -446.23 Thousand USD | -95.7% |
| 2019 Q2 | -228.02 Thousand USD | 39.22% |
| 2019 Q1 | -375.14 Thousand USD | 53.6% |
| 2019 Q4 | -647.92 Thousand USD | -45.2% |
| 2019 FY | -2.04 Million USD | -9.7% |
| 2018 Q3 | -167.77 Thousand USD | 72.63% |
| 2018 FY | -1.86 Million USD | -87.54% |
| 2018 Q1 | -277.63 Thousand USD | 5.85% |
| 2018 Q2 | -613.05 Thousand USD | -120.82% |
| 2018 Q4 | -808.44 Thousand USD | -381.87% |
| 2017 FY | -995.47 Thousand USD | 6.3% |
| 2017 Q4 | -294.89 Thousand USD | -10.55% |
| 2017 Q3 | -266.76 Thousand USD | -7.63% |
| 2017 Q2 | -247.86 Thousand USD | -33.29% |
| 2017 Q1 | -185.95 Thousand USD | 49.91% |
| 2016 Q4 | -371.25 Thousand USD | -103.15% |
| 2016 Q1 | -228.78 Thousand USD | -9.56% |
| 2016 Q3 | -182.74 Thousand USD | 34.65% |
| 2016 FY | -1.06 Million USD | -81.17% |
| 2016 Q2 | -279.66 Thousand USD | -22.24% |
| 2015 Q3 | -179.79 Thousand USD | -47.62% |
| 2015 Q4 | -208.82 Thousand USD | -16.14% |
| 2015 FY | -586.44 Thousand USD | -103.1% |
| 2015 Q1 | -76.22 Thousand USD | 65.13% |
| 2015 Q2 | -121.8 Thousand USD | -59.8% |
| 2014 FY | -288.75 Thousand USD | 47.66% |
| 2014 Q1 | -44.08 Thousand USD | 15.05% |
| 2014 Q4 | -218.58 Thousand USD | -726.42% |
| 2014 Q3 | 34.89 Thousand USD | 157.23% |
| 2014 Q2 | -60.97 Thousand USD | -38.3% |
| 2013 Q2 | -224.29 Thousand USD | -34.88% |
| 2013 FY | -551.65 Thousand USD | 31.52% |
| 2013 Q4 | -51.89 Thousand USD | 52.47% |
| 2013 Q1 | -166.28 Thousand USD | 49.43% |
| 2013 Q3 | -109.17 Thousand USD | 51.32% |
| 2012 Q1 | -377.63 Thousand USD | 29.21% |
| 2012 Q4 | -328.83 Thousand USD | -225.68% |
| 2012 Q3 | 261.64 Thousand USD | 172.54% |
| 2012 FY | -805.53 Thousand USD | 17.02% |
| 2012 Q2 | -360.7 Thousand USD | 4.48% |
| 2011 Q3 | -378.08 Thousand USD | -668.49% |
| 2011 Q4 | -533.47 Thousand USD | -41.1% |
| 2011 FY | -970.69 Thousand USD | -111.84% |
| 2011 Q1 | -9940.00 USD | -224.31% |
| 2011 Q2 | -49.19 Thousand USD | -394.95% |
| 2010 Q2 | -96.77 Thousand USD | 64.98% |
| 2010 Q4 | -3065.00 USD | 96.26% |
| 2010 Q3 | -82.02 Thousand USD | 15.23% |
| 2010 Q1 | -276.35 Thousand USD | 36.92% |
| 2010 FY | -458.22 Thousand USD | 70.2% |
| 2009 Q2 | -433.42 Thousand USD | -55.59% |
| 2009 FY | -1.53 Million USD | -1579.66% |
| 2009 Q3 | -393.28 Thousand USD | 9.26% |
| 2009 Q4 | -438.12 Thousand USD | -11.4% |
| 2009 Q1 | -278.57 Thousand USD | -61259.25% |
| 2008 Q2 | -44.94 Thousand USD | 18.24% |
| 2008 FY | -91.54 Thousand USD | -430.37% |
| 2008 Q3 | -5000.00 USD | 88.88% |
| 2008 Q4 | -454.00 USD | 90.92% |
| 2008 Q1 | -54.97 Thousand USD | -466.12% |
| 2007 Q3 | -7550.00 USD | 0.0% |
| 2007 FY | -17.26 Thousand USD | 0.0% |
| 2007 Q4 | -9711.00 USD | -28.62% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -62.48% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 68.926% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 104.096% |
| Nascent Biotech, Inc. | -2.08 Million USD | -3.934% |
| Rebus Holdings, Inc. | -1.02 Million USD | -112.727% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 103.331% |
| Qrons Inc. | -789.34 Thousand USD | -174.887% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -243.104% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 96.534% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -422.244% |
| Skye Bioscience, Inc. | -37.64 Million USD | 94.236% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.105% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 67.005% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -693.635% |
| SQZ Biotechnologies Company | -79.46 Million USD | 97.269% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 24.982% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -19.186% |
| Mesoblast Limited | -87.95 Million USD | 97.533% |
| Marizyme, Inc. | -65.34 Million USD | 96.68% |
| Genus plc | 7.9 Million USD | 127.466% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 80.078% |
| Pharming Group N.V. | -10.54 Million USD | 79.429% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 41.518% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 75.466% |
| ContraFect Corporation | -65.15 Million USD | 96.67% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 55.592% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -25.608% |
| IMV Inc. | -36.48 Million USD | 94.053% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 73.078% |
| MultiCell Technologies, Inc. | -380.07 USD | -570798.519% |
| ONE Bio Corp. | 8.67 Million USD | 125.008% |
| Accustem Sciences Inc. | -3.74 Million USD | 42.083% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 95.802% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -71.238% |
| Q BioMed Inc. | -2.05 Million USD | -5.737% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 41.875% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 8.865% |
| Biomind Labs Inc. | -1.21 Million USD | -78.686% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 96.367% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 30.046% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 72.545% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -11.315% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -14388.608% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 86.329% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 62.7% |
| GB Sciences, Inc. | -1.36 Million USD | -59.349% |
| Alpha Cognition Inc. | -13.77 Million USD | 84.245% |
| HST Global, Inc. | -146.21 Thousand USD | -1384.039% |
| CSL Limited | 2.64 Billion USD | 100.082% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -23.652% |
| Halberd Corporation | -79.67 Thousand USD | -2623.297% |
| Enzolytics Inc. | -2.17 Million USD | 0.322% |
| Agentix Corp. | -1.37 Million USD | -57.895% |
| Resverlogix Corp. | -3.61 Million USD | 39.894% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 31.583% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.265% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 2314.096% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 131.335% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 45.386% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 28.298% |
| AVAX Technologies, Inc. | -6.41 Million USD | 66.169% |
| Zenith Capital Corp. | -10.59 Million USD | 79.522% |
| Genscript Biotech Corporation | -95.47 Million USD | 97.727% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -9235.746% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 47.664% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -3489.994% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -8.214% |
| Kadimastem Ltd | -3.3 Million USD | 34.395% |
| Helix BioMedix, Inc. | -1.05 Million USD | -105.464% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 43.184% |
| BioStem Technologies, Inc. | -8.48 Million USD | 74.422% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -391.61% |
| LadRx Corporation | 400.44 Thousand USD | 641.853% |
| Cell Source, Inc. | -5.32 Million USD | 59.223% |
| Regen BioPharma, Inc. | 1.02 Million USD | 311.998% |
| Regen BioPharma, Inc. | 1.02 Million USD | 311.998% |
| NovAccess Global Inc. | -4.76 Million USD | 54.503% |
| Affymax, Inc. | -14.42 Million USD | 84.957% |
| Itoco Inc. | -1.86 Million USD | -16.095% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 51.158% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -30.007% |
| Mobile Lads Corp. | -2.26 Million USD | 4.13% |
| CytoDyn Inc. | -49.84 Million USD | 95.647% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -2645.453% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -851.143% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -130.456% |
| SYBLEU INC | -180.3 Thousand USD | -1103.42% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -34.542% |
| International Stem Cell Corporation | -131 Thousand USD | -1556.347% |
| Bioxytran, Inc. | -4.28 Million USD | 49.303% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -3898.036% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 14.245% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 95.486% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -2.64% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -177.865% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 31.508% |
| Neutra Corp. | -233.46 Thousand USD | -829.396% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 89.307% |
| PureTech Health plc | -65.69 Million USD | 96.697% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 89.797% |
| IXICO plc | -1.17 Million USD | -84.195% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 78.142% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 96.202% |
| CSL Limited | 2.64 Billion USD | 100.082% |
| Cellectis S.A. | -103.17 Million USD | 97.897% |